化学免疫疗法
淋巴瘤
队列
套细胞淋巴瘤
比例危险模型
医学
内科学
肿瘤科
国际预后指标
临床意义
生物
生物信息学
美罗华
作者
Mette Dahl,Simon Husby,Christian Winther Eskelund,Søren Besenbacher,Søren Fjelstrup,Christophé Côme,Sara Ek,Arne Kolstad,Riikka Räty,Mats Jerkeman,Christian H. Geisler,Jørgen Kjems,Lasse S. Kristensen,Kirsten Grønbæk
出处
期刊:Leukemia
[Springer Nature]
日期:2021-07-09
卷期号:36 (1): 177-188
被引量:19
标识
DOI:10.1038/s41375-021-01311-4
摘要
Mantle cell lymphoma (MCL) is characterized by marked differences in outcome, emphasizing the need for strong prognostic biomarkers. Here, we explore expression patterns and prognostic relevance of circular RNAs (circRNAs), a group of endogenous non-coding RNA molecules, in MCL. We profiled the circRNA expression landscape using RNA-sequencing and explored the prognostic potential of 40 abundant circRNAs in samples from the Nordic MCL2 and MCL3 clinical trials, using NanoString nCounter Technology. We report a circRNA-based signature (circSCORE) developed in the training cohort MCL2 that is highly predictive of time to progression (TTP) and lymphoma-specific survival (LSS). The dismal outcome observed in the large proportion of patients assigned to the circSCORE high-risk group was confirmed in the independent validation cohort MCL3, both in terms of TTP (HR 3.0; P = 0.0004) and LSS (HR 3.6; P = 0.001). In Cox multiple regression analysis incorporating MIPI, Ki67 index, blastoid morphology and presence of TP53 mutations, circSCORE retained prognostic significance for TTP (HR 3.2; P = 0.01) and LSS (HR 4.6; P = 0.01). In conclusion, circRNAs are promising prognostic biomarkers in MCL and circSCORE improves identification of high-risk disease among younger patients treated with cytarabine-containing chemoimmunotherapy and autologous stem cell transplant.
科研通智能强力驱动
Strongly Powered by AbleSci AI